Rituximab Journal Club

Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and Dependent Nephrotic Syndrome: Multicentric Report Ashima Gulati, Aditi Sinha, Stanley C. Jordan, Pankaj Hari, Amit K. Dinda, Sonika Sharma, Rajendra . Srivastava, Asha Moudgil, and Arvind Bagga Divisions of Pediatric Nephrology and Genetics, and Department of Pathology, AIIMS, New Delhi, India; Nephrology and Transplant Immunology, Cedars-Sinai Medical Center, Los Angeles; and Nephrology and Kidney Transplant, Children’s National Medical Center, Washington, DC

Nephrotic syndrome- why occurs? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Pediatr Nephrol (2009) 24:1433–1438

Evidence in support of B cell disease ,[object Object],[object Object],[object Object]

Pro-B Pre-B1 Pre-B2 Immature B Mature B Plasma MHC II CD19 CD22 CD34 Ig  VpreB,  5 CD10 CD20

Rituximab and B cells ,[object Object],[object Object],[object Object],[object Object]

Mechanism of Actions ,[object Object],[object Object],[object Object],[object Object],[object Object]

Rituximab and Cell death ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Course of Nephrotic Syndrome 40% 10-15% ISKDC. J Am Soc Nephrol 8: 769–776, 1997 Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol 4: 1593–1600, 2009

Difficult to manage ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Pediatr Nephrol 24: 1525–1532, 2009; Pediatr Nephrol 22: 215-221, 2007

Rituximab ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Semin Arthrit Rheum 36: 71–81, 2006 Pediatr Nephrol 24: 1433–1438, 2009

Rituximab in Nephrotic Syndrome ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Material and Methods ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Definitions ,[object Object],[object Object],[object Object],[object Object],[object Object]

Methods ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Rituximab Therapy in SRNS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Rituximab therapy in SDNS ,[object Object],[object Object],[object Object],[object Object]

Rituximab not used ,[object Object],[object Object],[object Object],[object Object],[object Object]

Rituximab Therapy ,[object Object],[object Object],[object Object],[object Object],[object Object]

Concomitant therapy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Follow-Up ,[object Object],[object Object],[object Object]

Results ,[object Object],[object Object],[object Object]

SRNS patients ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object]

Longer follow up ,[object Object],[object Object],[object Object],[object Object]

SRNS- Retreatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SDNS patients ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SDNS patients ,[object Object],[object Object],[object Object]

B-Cell (CD19) Depletion ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Side Effects ,[object Object],[object Object],[object Object],[object Object],[object Object]

Discussion ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SDNS patients ,[object Object],[object Object],[object Object],[object Object]

Sustained remission in 19 patients (86.3%),

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Critical Appraisal ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Side Effects ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Limitations ,[object Object],[object Object],[object Object],[object Object],[object Object]

Conclusions ,[object Object],[object Object],[object Object],[object Object]

Rituximab Journal Club

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Andere mochten auch

Andere mochten auch (13)

Ähnlich wie Rituximab Journal Club

Ähnlich wie Rituximab Journal Club (20)

Rituximab Journal Club